Inqovi (decitabine and cedazuridine)

  • Brand Name: Inqovi
  • Innovator Brand Name: Inqovi
  • API: Decitabine and Cedazuridine
  • Dosage Form: 5 Tablets
  • Strength: 35 mg Decitabine and 100 mg Cedazuridine
  • Manufacturer Name: Astex Pharmaceuticals, Inc.
Get Price

Description

Inqovi Uses:

Inqovi is a combination of decitabine (a nucleoside metabolic inhibitor), and cedazuridine (a cytidine deaminase inhibitor), used to treat adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1/2, and high-risk International Prognostic Scoring System groups.

Dosage: The recommended dosage of Inqovi is 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) administered orally once a day on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until the disease is progressive or unacceptable toxicity occur. A complete or partial response may take longer than 4 cycles. Take inqovi 35 mg-100 mg tablets at the same time each day. Swallow tablets whole. Do not cut/crush/chew your tablets. Avoid consuming food 2 hours before and 2 hours following each dose. In case the patient misses a dose within 12 hours of the time it is usually taken, patients are advised to take the missed dose quickly and then to resume the normal daily dosing schedule. The dosing period can be extended by one day for every missed dose to complete 5 daily doses for each cycle. Avoid taking an additional dose in case vomiting occurs after the dose of inqovi but continue with the next scheduled dose.

Side Effects: The most commonly reported inqovi side effects (incidence ≥20%) include:

  • Fatigue
  • Constipation
  • Hemorrhage
  • Myalgia
  • Mucositis
  • Arthralgia
  • Nausea
  • Dyspnea
  • Diarrhea
  • Rash
  • Dizziness
  • Febrile neutropenia
  • Edema
  • Headache
  • Cough
  • Decreased appetite
  • Upper respiratory tract infection
  • Pneumonia
  • Transaminase increased

Warnings and Precautions:

  • Complete blood cell counts should be obtained prior to initiation of therapy with inqovi tablets, prior to each cycle, and as clinically indicated to evaluate response and toxicity.
  • All the respective women should not breastfeed during therapy with decitabine/cedazuridine dosage and for two weeks after the last dose.
  • All the females of reproductive age or potential should inform their health specialist of a known or suspected pregnancy. Patients should take decitabine plus cedazuridine at around the same time each day on an empty stomach. Do not eat for at least two hours before and two hours after taking the medication.

More info

Storage: Store Decitabine and Cedazuridine tablets at 20°C-25°C (68°F-77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense it in the original packaging. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the INQOVI at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the INQOVI Tablets. Buying Procedure: In order to buy INQOVI, you can contact us at our TOLL-FREE Number 1800 889 1064 or on WhatsApp Number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusions: Efficacy and safety from the oral decitabine 35 mg/ cedazuridine 100 mg daily for five days every 28 days are consistent with historical clinical findings from standard IV decitabine 20 mg/m2 daily for five days. Oral decitabine/cedazuridine is the only oral HMA with the systemic exposure equivalent to its injectable drug. Further investigation of oral decitabine and cedazuridine in all-oral combination findings is warranted and underway.

FAQ

What is Inqovi? Inqovi is a prescription medicine introduced to treat adult patients with MDS (myelodysplastic syndromes), including chronic myelomonocytic leukemia (CMML). What does Inqovi contain as an active substance? The medication Inqovi specifically contains the active substance Decitabine and Cedazuridine. How much does inqovi cost? The inqovi price in India usually can vary depending on the wholesaler/pharmacy you visit. Inqovi is available as a brand name drug only, a generic version is not yet available. What is the best price for Decitabine and Cedazuridine? Please contact Toll-free: +91 1800 889 1064|+919310090915 for decitabine and cedazuridine price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Inqovi (Decitabine and Cedazuridine) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Inqovi (Decitabine and Cedazuridine), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

×